Procopio Priscilla Francesca, Pennestrì Francesco, Laurino Antonio, Rossi Esther Diana, Schinzari Giovanni, Pontecorvi Alfredo, De Crea Carmela, Raffaelli Marco
U.O.C. Chirurgia Endocrina E Metabolica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Centro Di Ricerca in Chirurgia Delle Ghiandole Endocrine E Obesità, Università Cattolica del Sacro Cuore, Rome, Italy.
Updates Surg. 2025 May 3. doi: 10.1007/s13304-025-02215-z.
In locally advanced adrenocortical carcinoma (ACC) (ENSAT stage III - S-III) R0 surgery, involving en bloc extended resections, is the only potential curative treatment. We evaluated oncological outcomes and complications rate in S-III patients who underwent extended resection in comparison with stage I/II (S-I/II). Among 1098 adrenalectomies over 27 years (1997 -2024) in a tertiary referral center, medical records of ACC patients were reviewed, excluding stage IV and not-multivisceral resections in S-III patients. Forty-eight patients met the inclusion criteria: 6 S-I (12.5%), 36 S-II (75%) and 6 S-III (12.5%) patients. The latter patients' cohort underwent multivisceral en bloc resections (3 total nephrectomies, one renal vein thrombectomy, one splenopancreasectomy associated with total nephrectomy, left hemicolectomy and omentectomy, one liver S6-S7-S8 resection). Open adrenalectomy was scheduled in all S-III patients. Minimally-invasive approach was scheduled in 21 (50%) S-I/II patients. Conversion to open adrenalectomy was registered in 5 out these 21 patients. Locoregional and distant disease recurrences were registered in 19% of S-I/II vs 33.3% of S-III patients and 28.6% of S-I/II vs 66.7% of S-III patients, respectively (p = 0.420, p = 0.064). Postoperative complications were observed in 21.4% of S-I/II patients and 16.7% of S-III patients (p = 0.788). Kaplan-Meier DFS and OS curves were comparable among the two groups (p = 0.255, p = 0.459, respectively). After univariable analysis, hyperfunction and chemotherapy were significantly associated with locoregional disease recurrence (p = 0.02, p = 0.04, respectively). OS and DFS of S-III ACC patients undergoing extended en bloc R0 resections were comparable to those of S-I/II patients, without increased postoperative morbidity.
在局部晚期肾上腺皮质癌(ACC)(欧洲肾上腺肿瘤研究网络(ENSAT)III期 - S-III期)中,R0手术(包括整块扩大切除术)是唯一可能的治愈性治疗方法。我们评估了接受扩大切除术的S-III期患者与I/II期(S-I/II期)患者的肿瘤学结局和并发症发生率。在一家三级转诊中心27年(1997 - 2024年)期间进行的1098例肾上腺切除术中,对ACC患者的病历进行了回顾,排除IV期患者以及S-III期患者中未进行多脏器切除术的病例。48例患者符合纳入标准:6例S-I期(12.5%)、36例S-II期(75%)和6例S-III期(12.5%)患者。后一组患者接受了多脏器整块切除术(3例全肾切除术、1例肾静脉血栓切除术、1例与全肾切除术相关的脾胰切除术、左半结肠切除术和大网膜切除术、1例肝S6 - S7 - S8段切除术)。所有S-III期患者均计划进行开放性肾上腺切除术。21例(50%)S-I/II期患者计划采用微创方法。这21例患者中有5例转为开放性肾上腺切除术。S-I/II期患者局部和远处疾病复发率分别为19%和33.3%,S-I/II期患者和S-III期患者分别为28.6%和66.7%(p = 0.420,p = 0.064)。S-I/II期患者术后并发症发生率为21.4%,S-III期患者为16.7%(p = 0.788)。两组的Kaplan-Meier无病生存期(DFS)和总生存期(OS)曲线具有可比性(分别为p = 0.255,p = 0.459)。单因素分析后,功能亢进和化疗与局部疾病复发显著相关(分别为p = 0.02,p = 0.04)。接受扩大整块R0切除术的S-III期ACC患者的OS和DFS与S-I/II期患者相当,且术后发病率没有增加。